This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Salinomycin
DrugBank Accession Number
DB11544
Background

Not Available

Type
Small Molecule
Groups
Vet approved
Structure
Weight
Average: 751.011
Monoisotopic: 750.491813074
Chemical Formula
C42H70O11
Synonyms
  • Procoxacin
  • Salinomycin

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcenocoumarolThe risk or severity of bleeding can be increased when Salinomycin is combined with Acenocoumarol.
ArticaineThe risk or severity of methemoglobinemia can be increased when Salinomycin is combined with Articaine.
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Salinomycin.
BenzocaineThe risk or severity of methemoglobinemia can be increased when Salinomycin is combined with Benzocaine.
Benzyl alcoholThe risk or severity of methemoglobinemia can be increased when Salinomycin is combined with Benzyl alcohol.
BupivacaineThe risk or severity of methemoglobinemia can be increased when Salinomycin is combined with Bupivacaine.
ButacaineThe risk or severity of methemoglobinemia can be increased when Salinomycin is combined with Butacaine.
ButambenThe risk or severity of methemoglobinemia can be increased when Salinomycin is combined with Butamben.
CapsaicinThe risk or severity of methemoglobinemia can be increased when Salinomycin is combined with Capsaicin.
ChloroprocaineThe risk or severity of methemoglobinemia can be increased when Salinomycin is combined with Chloroprocaine.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Salinomycin sodium92UOD3BMEK55721-31-8YPZYGIQXBGHDBH-UZHRAPRISA-M

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as diterpene glycosides. These are diterpenoids in which an isoprene unit is glycosylated.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Terpene glycosides
Direct Parent
Diterpene glycosides
Alternative Parents
Diterpenoids / Fatty alcohols / Branched fatty acids / Heterocyclic fatty acids / Hydroxy fatty acids / Ketals / Beta-hydroxy ketones / Oxanes / Pyrans / Tertiary alcohols
show 8 more
Substituents
Acetal / Alcohol / Aliphatic heteropolycyclic compound / Beta-hydroxy ketone / Branched fatty acid / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Dialkyl ether / Diterpene glycoside
show 20 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
diterpene glycoside (CHEBI:80025)
Affected organisms
Not Available

Chemical Identifiers

UNII
62UXS86T64
CAS number
53003-10-4
InChI Key
KQXDHUJYNAXLNZ-XQSDOZFQSA-N
InChI
InChI=1S/C42H70O11/c1-11-29(38(46)47)31-15-14-23(4)36(50-31)27(8)34(44)26(7)35(45)30(12-2)37-24(5)22-25(6)41(51-37)19-16-32(43)42(53-41)21-20-39(10,52-42)33-17-18-40(48,13-3)28(9)49-33/h16,19,23-34,36-37,43-44,48H,11-15,17-18,20-22H2,1-10H3,(H,46,47)/t23-,24-,25+,26-,27-,28-,29+,30-,31+,32+,33+,34+,36+,37-,39-,40+,41-,42-/m0/s1
IUPAC Name
(2R)-2-[(2R,5S,6R)-6-[(2S,3S,4S,6R)-6-[(2S,5S,7R,9S,10S,12R,15R)-2-[(2R,5R,6S)-5-ethyl-5-hydroxy-6-methyloxan-2-yl]-15-hydroxy-2,10,12-trimethyl-1,6,8-trioxadispiro[4.1.5⁷.3⁵]pentadec-13-en-9-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-5-methyloxan-2-yl]butanoic acid
SMILES
[H][C@@](C)(C(=O)[C@]([H])(CC)[C@@]1([H])O[C@@]2(O[C@@]3(CC[C@](C)(O3)[C@@]3([H])CC[C@](O)(CC)[C@]([H])(C)O3)[C@]([H])(O)C=C2)[C@]([H])(C)C[C@]1([H])C)[C@@]([H])(O)[C@]([H])(C)[C@]1([H])O[C@]([H])(CC[C@]1([H])C)[C@@]([H])(CC)C(O)=O

References

General References
  1. Potter LM, Blake JP, Blair ME, Bliss BA, Denbow DM: Salinomycin toxicity in turkeys. Poult Sci. 1986 Oct;65(10):1955-9. [Article]
  2. Horrox NE: Salinomycin poisoning in turkeys. Vet Rec. 1984 Jan 14;114(2):52. [Article]
  3. Aleman M, Magdesian KG, Peterson TS, Galey FD: Salinomycin toxicosis in horses. J Am Vet Med Assoc. 2007 Jun 15;230(12):1822-6. [Article]
  4. Rollinson J, Taylor FG, Chesney J: Salinomycin poisoning in horses. Vet Rec. 1987 Aug 8;121(6):126-8. [Article]
  5. Pott JM: Salinomycin toxicity in pigs. Vet Rec. 1990 Dec 1;127(22):554. [Article]
  6. Vertesy L, Heil K, Fehlhaber HW, Ziegler W: Microbial decomposition of salinomycin. J Antibiot (Tokyo). 1987 Mar;40(3):388-90. [Article]
  7. Stuart JC: Salinomycin poisoning in turkeys. Vet Rec. 1983 Dec 17;113(25):597. [Article]
  8. Kavanagh NT, Sparrow DS: Salinomycin toxicity in pigs. Vet Rec. 1990 Nov 17;127(20):507. [Article]
  9. Harries N: Alberta. Salinomycin toxicity in turkeys. Can Vet J. 1991 Feb;32(2):117. [Article]
  10. Huyben MW, Sol J, Counotte GH, Roumen MP, Borst GH: Salinomycin poisoning in veal calves. Vet Rec. 2001 Aug 11;149(6):183-4. [Article]
KEGG Drug
D08502
KEGG Compound
C15690
ChemSpider
2342058
RxNav
1311566
ChEBI
80025
ChEMBL
CHEMBL1208572
ZINC
ZINC000085540254
Wikipedia
Salinomycin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00297 mg/mLALOGPS
logP4.48ALOGPS
logP7.51Chemaxon
logS-5.4ALOGPS
pKa (Strongest Acidic)4.45Chemaxon
pKa (Strongest Basic)-3Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count11Chemaxon
Hydrogen Donor Count4Chemaxon
Polar Surface Area161.21 Å2Chemaxon
Rotatable Bond Count12Chemaxon
Refractivity200.07 m3·mol-1Chemaxon
Polarizability81.82 Å3Chemaxon
Number of Rings5Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Riccioni R, Dupuis ML, Bernabei M, Petrucci E, Pasquini L, Mariani G, Cianfriglia M, Testa U: The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor. Blood Cells Mol Dis. 2010 Jun 15;45(1):86-92. doi: 10.1016/j.bcmd.2010.03.008. Epub 2010 May 4. [Article]
  2. Kim WK, Kim JH, Yoon K, Kim S, Ro J, Kang HS, Yoon S: Salinomycin, a p-glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing G2 arrest. Invest New Drugs. 2012 Aug;30(4):1311-8. doi: 10.1007/s10637-011-9685-6. Epub 2011 May 15. [Article]

Drug created at February 26, 2016 17:41 / Updated at February 21, 2021 18:53